Table 1 Patient demographics
Number of patients (male/female) | 151 | (63/88) |
|---|---|---|
Age, median (min-max) | 60 | (28–82) |
Number of chemotherapy courses | 210 | |
Cancer | ||
 Breast cancer | 42 | 27.8% |
 Colorectal cancer | 40 | 26.5% |
 Pancreatic cancer | 20 | 13.2% |
 Gastric cancer | 17 | 11.3% |
 Head and neck cancer | 9 | 6.0% |
 Lung cancer | 9 | 6.0% |
 Ovarian cancer/cervical cancer/uterine cancer | 5 | 3.3% |
 Biliary tract cancer | 4 | 2.6% |
 Angiosarcoma | 1 | 0.7% |
 Esophageal cancer | 1 | 0.7% |
 Malignant lymphoma | 1 | 0.7% |
 Malignant pleural mesothelioma | 1 | 0.7% |
 Peritoneal cancer | 1 | 0.7% |
Regimen | ||
 L-OHP + fluoropyrimidines±Bmab/Pmab/Tmab | 32 | 21.2% |
 PTX/Nab-PTX ± Tmab/ramucirumab/Bmab/Cmab | 27 | 17.9% |
 Anthracyclines+cyclophosphamide | 17 | 11.3% |
 GEM+Nab-PTX | 12 | 7.9% |
CPT-11 ± fluoropyrimidines±Bmab/aflibercept/ramucirumab/Pmab | 11 | 7.3% |
 DOC/GEM/EPI/VNR/NabPTX+PER+Tmab | 10 | 6.6% |
 FOLFIRINOX/FOLFOXIRI+Bmab | 8 | 5.3% |
 CBDCA±PEM ± Bmab±Cmab | 7 | 4.6% |
 GEM±S-1 ± CDDP | 7 | 4.6% |
 Pembrolizumab/nivolumab/durvalmab/atezolizumab | 6 | 4.0% |
 TAS102 + Bmab | 4 | 2.6% |
 DOC/LipoDOX±Bmab | 3 | 2.0% |
 Maintenance chemotherapy (Tmab/rituximab) | 2 | 1.3% |
 S-1 + DOC | 2 | 1.3% |
 Other (CMF/Eribulin/T-DM1) | 3 | 2.0% |